More shots of potential

chris.truelove

By Christiane Truelove (chris.truelove@ubm.com)

According to analysts at Evaluate Pharma, the market for vaccines will grow from $ 25.47 billion in sales in 2012 to $ 38.88 billion in 2018. The top pharmaceutical company in the vaccines space by 2018 will be Sanofi, with sales of $ 8.7 billion, or 22.4 percent of the market. These sales include the company’s 50 percent share of the Sanofi Pasteur MSD joint venture with Merck & Co.

The second-largest vaccines company during 2018 will be Merck. Aided by its 50 percent share of Sanofi Pasteur MSD, Evaluate Pharma predicts 2018 sales of $ 7.84 billion for Merck. GlaxoSmithKline will be No. 3 by 2018, with predicted sales of $ 6.97 billion. Pfizer will be No. 4, with sales of $ 6.74 billion. Sales of Pfizer’s Prevnar 13 continue to show strong year-on-year growth of 8 percent and the product is expected to account for 15.6 percent of the vaccine market by 2018. No. 5 in the vaccines market by 2018 will be Novartis, with sales of $ 2.75 billion.

With Prevnar at the top, Evaluate Pharma predicts that the No. 2 vaccine product in the world by 2018 will be PENTact-HIB, Sanofi’s vaccine against diphtheria, tetanus, pertussis, Haemophilus influenzae B, and polio. The product is forecast to have sales of $ 2.35 billion by 2018, up from 2012 sales of $ 1.52 billion. The No. 3 vaccine in terms of sales will be Merck’s HPV product Gardasil, which is expected to hit $ 2.26 billion in 2018, up from $ 1.63 billion in 2012.

At No. 4 will be Sanofi’s flu vaccine Fluzone/Vaxigrip, with sales of $ 1.79 billion in 2018, up from $ 1.14 billion in 2012.
The No. 5 vaccine in terms of sales is expected to be Merck’s varicella vaccine Varivax, which is expected to achieve $ 1.48 billion by 2018, up from $ 1.27 billion in 2012.

The vaccines awaiting approval and in late-stage development represent a spectrum of diseases. Though a large number of them focus on…Read more

Pharmalive – The Pulse of the Pharmaceutical Industry

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS